AMPK, insulin resistance, and the metabolic syndrome

Journal of Clinical Investigation

Volumn 123, Issue 7, 2013, Pages 2764-2772

  Ruderman, Neil B ^a   Carling, David ^b   Prentki, Marc ^c,d   Cacicedo, José M ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLAMMASOME; INTERLEUKIN 10; METFORMIN; RESVERATROL; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADIPOSE TISSUE; BARIATRIC SURGERY; BLOOD PRESSURE MEASUREMENT; CAPILLARY DENSITY; CARDIOVASCULAR RISK; CIRCADIAN RHYTHM; COMPETITIVE INHIBITION; DISEASE ASSOCIATION; DOWN REGULATION; ENZYME ACTIVATION; EXERCISE; FATTY ACID OXIDATION; GLYCEMIC CONTROL; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; MACROPHAGE ACTIVATION; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; PATHOGENESIS; PHENOTYPE; PHYSICAL ACTIVITY; PRIORITY JOURNAL; REVIEW; SKELETAL MUSCLE; STRUCTURE ACTIVITY RELATION; VASCULAR ENDOTHELIUM; WAIST CIRCUMFERENCE;

ADENYLATE KINASE; ADIPOSE TISSUE; ANIMALS; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVATORS; HUMANS; INSULIN RESISTANCE; MACROPHAGE ACTIVATION; METABOLIC SYNDROME X; OBESITY; OXIDATIVE STRESS; SIRTUIN 1;

EID: 84879621442     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI67227     Document Type: Review

References (151)

1. Carling D, Zammit VA, Hardie DG. A common bicyclic protein kinase cascade inactivates the regulatory enzymes of fatty acid and cholesterol biosynthesis. FEBS Lett. 1987;223(2):217-222.
2. Kahn BB, Alquier T, Carling D, Hardie DG. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab. 2005;1(1):15-25. (Pubitemid 43960587)
3. Ruderman NB, Prentki M. AMP kinase and malonyl-CoA: targets for therapy of the metabolic syndrome. Nat Rev Drug Discov. 2004;3(4):340-351. (Pubitemid 38499761)
4. Ruderman NB, Saha AK, Vavvas D, Witters LA. Malonyl-CoA, fuel sensing, and insulin resistance. Am J Physiol. 1999;276(1 pt 1):E1-E18. (Pubitemid 29065588)
5. Salminen A, Hyttinen JM, Kaarniranta K. AMP-activated protein kinase inhibits NF-κB signaling and inflammation: impact on healthspan and lifespan. J Mol Med. 2011;89(7):667-676.
6. Steinberg GR, Kemp BE. AMPK in health and disease. Physiol Rev. 2009;89(3):1025-1078.
7. Viollet B, Andreelli F. AMP-activated protein kinase and metabolic control. Handb Exp Pharmacol. 2011;(203):303-330.
8. Winder WW, Hardie DG. AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes. Am J Physiol. 1999;277(1 pt 1):E1-E10. (Pubitemid 29356721)
9. Winder WW, Hardie DG. Inactivation of acetyl-CoA carboxylase and activation of AMP-activated protein kinase in muscle during exercise. Am J Physiol. 1996;270(2 pt 1):E299-E304.
10. Vavvas D, et al. Contraction-induced changes in acetyl-CoA carboxylase and 5′-AMP-activated kinase in skeletal muscle. J Biol Chem. 1997;272(20):13255-13261. (Pubitemid 27216754)
11. Bjorntorp P, De Jounge K, Sjostrom L, Sullivan L. The effect of physical training on insulin production in obesity. Metabolism. 1970;19(8):631-638.
12. Bjorntorp P, Fahlen M, Grimby G. Carbohydrate and lipid metabolism in middle-aged, physically well-trained men. Metabolism. 1972;21(11):1037-1044.
13. Ruderman NB, et al. AMPK and SIRT1: a long-standing partnership? Am J Physiol Endocrinol Metab. 2010;298(4):E751-E760.
14. Kola B, et al. Changes in adenosine 5′-monophosphate-activated protein kinase as a mechanism of visceral obesity in Cushing's syndrome. J Clin Endocrinol Metab. 2008;93(12):4969-4973.
15. Gauthier MS, et al. Decreased AMP-activated protein kinase activity is associated wtih increased inflammation in visceral adipose tissue and with whole-body insulin resistance in morbidly obese humans. Biochem Biophys Res Commun. 2011;404(1):382-387.
16. Xu XJ, et al. Insulin sensitive and resistant obesity in humans: AMPK activity, oxidative stress, and depot-specific changes in gene expression in adipose tissue. J Lipid Res. 2012;53(4):792-801.
17. Sjöström L, et al. Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial. Lancet Oncol. 2009;10(7):653-662.
18. Sjöström L, et al. Bariatric surgery and long-term cardiovascular events. JAMA. 2012;307(1):56-65.
19. Xu XJ, Pories WJ, Dohm LG, Ruderman NB. What distinguishes adipose tissue of severely obese humans who are insulin sensitive and resistant? Curr Opin Lipidol. 2013;24(1):49-56.
20. Goodman MN, Ruderman NB. Insulin sensitivity of rat skeletal muscle: effects of starvation and aging. Am J Physiol. 1979;236(5):E519-E523. (Pubitemid 9191783)
21. Richter EA, Garetto LP, Goodman MN, Ruderman NB. Muscle glucose metabolism following exercise in the rat: increased sensitivity to insulin. J Clin Invest. 1982;69(4):785-793. (Pubitemid 12149155)
22. Richter EA, Ruderman NB. AMPK and the biochemistry of exercise: implications for human health and disease. Biochem J. 2009;418(2):261-275.
23. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37(12):1595-1607. (Pubitemid 19004941)
24. Ruderman NB, Shulman GI. The metabolic syndrome. In: Jamieson JL, DeGroot LJ, eds. Textbook of Endocrinology. 6th ed. Philadelphia, Pennsylvania: Elsevier; 2010:822-839.
25. Nolan CJ, Damm P, Prentki M. Type 2 diabetes across generations: from pathophysiology to prevention and management. Lancet. 2011;378(9786):169-181.
26. Nolan CJ, Ruderman NB, Prentki M. Intensive use of insulin in type 2 diabetes: the risk of causing harm. The Lancet Diabetes & Endocrinology. In press.
27. Alberti KG, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640-1645.
28. Ruderman NB, Chisholm D, Pi-Sunyer X, Schneider S. The metabolically obese, normal-weight individual revisited. Diabetes. 1998;47(5):699-713. (Pubitemid 28201798)
29. Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care. 2004;27(3):813-823. (Pubitemid 38280558)
30. Xiao B, et al. Structure of mammalian AMPK and its regulation by ADP. Nature. 2011;472(7342):230-233.
31. Oakhill JS, et al. AMPK is a direct adenylate charge-regulated protein kinase. Science. 2011;332(6036):1433-1435.
32. Sanders MJ, Ali ZS, Hegarty BD, Heath R, Snowden MA, Carling D. Defining the mechanism of activation of AMP-activated protein kinase by the small molecule A-769662, a member of the thienopyridone family. J Biol Chem. 2007;282(45):32539-32548. (Pubitemid 350159309)
33. Racioppi L, Means AR. Calcium/calmodulin-dependent protein kinase kinase 2: roles in signaling and pathophysiology. J Biol Chem. 2012;287(38):31658- 31665.
34. 2+/ calmodulin-dependent protein kinase kinase beta. Mol Cell Biol. 2006;26(16):5933-5945.
35. [No authors listed]. Surgeon General's report on physical activity and health. From the Centers for Disease Control and Prevention. JAMA. 1996;276(7):522.
36. Paffenbarger RS Jr, Wing AL, Hyde RT. Physical activity as an index of heart attack risk in college alumni. Am J Epidemiol. 1978;108(3):161-175. (Pubitemid 9167225)
37. Frisch RE, Wyshak G, Albright TE, Albright NL, Schiff I. Lower prevalence of diabetes in female former college athletes compared with nonathletes. Diabetes. 1986;35(10):1101-1105. (Pubitemid 17176953)
38. Knowler WC, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393-403. (Pubitemid 34437694)
39. Tuomilehto J, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344(18):1343-1350. (Pubitemid 32378388)
40. Park H, et al. Coordinate regulation of malonyl-CoA decarboxylase, sn-glycerol-3-phosphate acyltransferase, and acetyl-CoA carboxylase by AMP-activated protein kinase in rat tissues in response to exercise. J Biol Chem. 2002;277(36):32571-32577. (Pubitemid 34984761)
41. Cacicedo JM, Gauthier MS, Lebrasseur NK, Jasuja R, Ruderman NB, Ido Y. Acute exercise activates AMPK and eNOS in the mouse aorta. Am J Physiol Heart Circ Physiol. 2011;301(4):H1255-H1265.
42. Zhang QJ, McMillin SL, Tanner JM, Palionyte M, Abel ED, Symons JD. Endothelial nitric oxide synthase phosphorylation in treadmill-running mice: role of vascular signalling kinases. J Physiol. 2009;587(pt 15):3911-3920.
43. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res. 2000;87(10):840-844.
44. Zhou G, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001;108(8):1167-1174. (Pubitemid 32995375)
45. [No authors listed]. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):854- 865.
46. Soranna D, et al. Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis. Oncologist. 2012;17(6):813-822.
47. Stevens RJ, et al. Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials. Diabetologia. 2012;55(10):2593-2603.
48. Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F. Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond). 2012;122(6):253-270.
49. Miller RA, Chu Q, Xie J, Foretz M, Viollet B, Birnbaum MJ. Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature. 2013;494(7436):256-260.
50. Tomas E, et al. Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc Natl Acad Sci U S A. 2002;99(25):16309-16313. (Pubitemid 35462791)
51. Yamauchi T, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med. 2002;8(11):1288-1295. (Pubitemid 35373562)
52. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev. 2005;26(3):439-451. (Pubitemid 40686653)
53. Scherer PE. Adipose tissue: from lipid storage compartment to endocrine organ. Diabetes. 2006;55(6):1537-1545. (Pubitemid 44324105)
54. Yamauchi T, Kadowaki T. Adiponectin receptor as a key player in healthy longevity and obesity-related diseases. Cell Metab. 2013;17(2):185-196.
55. 2+) and AMPK/SIRT1. Nature. 2010;464(7293):1313- 1319.
56. Saha AK, Avilucea PR, Ye JM, Assifi MM, Kraegen EW, Ruderman NB. Pioglitazone treatment activates AMP-activated protein kinase in rat liver and adipose tissue in vivo. Biochem Biophys Res Commun. 2004;314(2):580-585. (Pubitemid 38084758)
57. Fryer LG, Parbu-Patel A, Carling D. The Anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem. 2002;277(28):25226-25232. (Pubitemid 34951829)
58. LeBrasseur NK, et al. Thiazolidinediones can rapidly activate AMP-activated protein kinase in mammalian tissues. Am J Physiol Endocrinol Metab. 2006;291(1):E175-E181. (Pubitemid 44035323)
59. Nawrocki AR, et al. Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor gamma agonists. J Biol Chem. 2006;281(5):2654-2660. (Pubitemid 43845727)
60. Kubota N, et al. Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and -independent pathways. J Biol Chem. 2006;281(13):8748-8755. (Pubitemid 43847980)
61. Kintscher U, Law RE. PPARgamma-mediated insulin sensitization: the importance of fat versus muscle. Am J Physiol Endocrinol Metab. 2005;288(2):E287-E291. (Pubitemid 40110633)
62. DeFronzo RA, et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med. 2011;364(12):1104-1115.
63. Tchernof A, Despres JP. Pathophysiology of human visceral obesity: an update. Physiol Rev. 2013;93(1):359-404.
64. Carling D, Thornton C, Woods A, Sanders MJ. AMP-activated protein kinase: new regulation, new roles? Biochem J. 2012;445(1):11-27.
65. Hardie DG. AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function. Genes Dev. 2011;25(18):1895-1908.
66. Zhang BB, Zhou G, Li C. AMPK: an emerging drug target for diabetes and the metabolic syndrome. Cell Metab. 2009;9(5):407-416.
67. Hardie DG, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol. 2012;13(4):251-262.
68. Svegliati-Baroni G, et al. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis. Liver Int. 2011;31(9):1285-1297.
69. Hawley SA, et al. The ancient drug salicylate directly activates AMP-activated protein kinase. Science. 2012;336(6083):918-922.
70. Buhl ES, et al. Long-term AICAR administration reduces metabolic disturbances and lowers blood pressure in rats displaying features of the insulin resistance syndrome. Diabetes. 2002;51(7):2199-2206. (Pubitemid 34729025)
71. Halseth AE, Ensor NJ, White TA, Ross SA, Gulve EA. Acute and chronic treatment of ob/ob and db/db mice with AICAR decreases blood glucose concentrations. Biochem Biophys Res Commun. 2002;294(4):798-805. (Pubitemid 34687187)
72. Song XM, et al. 5-Aminoimidazole-4-carboxamide ribonucleoside treatment improves glucose homeostasis in insulin-resistant diabetic (ob/ob) mice. Diabetologia. 2002;45(1):56-65. (Pubitemid 34118543)
73. Bergeron R, et al. Effect of AMPK activation on muscle glucose metabolism in conscious rats. Am J Physiol. 1999;276(5 pt 1):E938-E944. (Pubitemid 29249614)
74. Yu X, et al. Leptinomimetic effects of the AMP kinase activator AICAR in leptin-resistant rats: prevention of diabetes and ectopic lipid deposition. Diabetologia. 2004;47(11):2012-2021. (Pubitemid 40110213)
75. Pold R, et al. Long-term AICAR administration and exercise prevents diabetes in ZDF rats. Diabetes. 2005;54(4):928-934. (Pubitemid 40446305)
76. de Souza CJ, Yu JH, Robinson DD, Ulrich RG, Meglasson MD. Insulin secretory defect in Zucker fa/fa rats is improved by ameliorating insulin resistance. Diabetes. 1995;44(8):984-991.
77. Matthaei S, et al. In vivo metformin treatment ameliorates insulin resistance: evidence for potentiation of insulin-induced translocation and increased functional activity of glucose transporters in obese (fa/fa) Zucker rat adipocytes. Endocrinology. 1993;133(1):304-311. (Pubitemid 23206408)
78. Hardie DG, Carling D, Gamblin SJ. AMP-activated protein kinase: also regulated by ADP? Trends Biochem Sci. 2011;36(9):470-477.
79. O'Neill HM. AMPK and exercise: glucose uptake and insulin sensitivity. Diabetes Metab J. 2013;37(1):1-21.
80. Dasgupta B, et al. The AMPK beta2 subunit is required for energy homeostasis during metabolic stress. Mol Cell Biol. 2012;32(14):2837-2848.
81. Fujii N, et al. Ablation of AMP-activated protein kinase alpha2 activity exacerbates insulin resistance induced by high-fat feeding of mice. Diabetes. 2008;57(11):2958-2966.
82. Um JH, et al. AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes. 2010;59(3):554-563.
83. Jelenik T, et al. AMP-activated protein kinase alpha2 subunit is required for the preservation of hepatic insulin sensitivity by n-3 polyunsaturated fatty acids. Diabetes. 2010;59(11):2737-2746.
84. Sinclair DA, Guarente L. Unlocking the secrets of longevity genes. Sci Am. 2006;294(3):48-51.
85. Hall JA, Dominy JE, Lee Y, Puigserver P. The sirtuin family's role in aging and age-associated pathologies. J Clin Invest. 2013;123(3):973-979.
86. Lan F, Cacicedo J, Ruderman N, Ido Y. SIRT1 modulation of the acetylation status, cytosolic localization, and activity of LKB1. Possible role in AMP-activated protein kinase activation. J Biol Chem. 2008;283(41):27628-27635.
87. Hou X, et al. SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase. J Biol Chem. 2008;283(29):20015-20026.
88. Price NL, et al. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab. 2012;15(5):675-690.
89. + metabolism and SIRT1 activity. Nature. 2009;458(7241):1056-1060.
90. Zang M, et al. Polyphenols stimulate AMP-activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor-deficient mice. Diabetes. 2006;55(8):2180-2191. (Pubitemid 44743614)
91. Prentki M, Madiraju SR. Glycerolipid/free fatty acid cycle and islet beta-cell function in health, obesity and diabetes. Mol Cell Endocrinol. 2012;353(1-2):88-100.
92. Ido Y, Carling D, Ruderman N. Hyperglycemia-induced apoptosis in human umbilical vein endothelial cells: inhibition by the AMP-activated protein kinase activation. Diabetes. 2002;51(1):159-167. (Pubitemid 34517993)
93. Hattori Y, Suzuki K, Hattori S, Kasai K. Metformin inhibits cytokine-induced nuclear factor kappaB activation via AMP-activated protein kinase activation in vascular endothelial cells. Hypertension. 2006;47(6):1183-1188. (Pubitemid 44289177)
94. Kukidome D, et al. Activation of AMP-activated protein kinase reduces hyperglycemia-induced mitochondrial reactive oxygen species production and promotes mitochondrial biogenesis in human umbilical vein endothelial cells. Diabetes. 2006;55(1):120-127. (Pubitemid 43343306)
95. Cacicedo JM, Yagihashi N, Keaney JF, Ruderman NB, Ido Y. AMPK inhibits fatty acid-induced increases in NF-kappaB transactivation in cultured human umbilical vein endothelial cells. Biochem Biophys Res Commun. 2004;324(4):1204-1209. (Pubitemid 40292150)
96. Ruderman NB, et al. Malonyl-CoA and AMP-activated protein kinase (AMPK): possible links between insulin resistance in muscle and early endothelial cell damage in diabetes. Biochem Soc Trans. 2003;31(pt 1):202-206. (Pubitemid 36241428)
97. Chen ZP, et al. AMP-activated protein kinase phosphorylation of endothelial NO synthase. FEBS Lett. 1999;443(3):285-289.
98. Sun W, et al. Statins activate AMP-activated protein kinase in vitro and in vivo. Circulation. 2006;114(24):2655-2662. (Pubitemid 44967349)
99. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature. 2011;473(7347):317-325.
100. Dong Y, et al. Reduction of AMP-activated protein kinase alpha2 increases endoplasmic reticulum stress and atherosclerosis in vivo. Circulation. 2010;121(6):792-803.
101. Wang Q, Zhang M, Liang B, Shirwany N, Zhu Y, Zou MH. Activation of AMP-activated protein kinase is required for berberine-induced reduction of atherosclerosis in mice: the role of uncoupling protein 2. PLoS One. 2011;6(9):e25436.
102. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003;112(12):1796-1808. (Pubitemid 38063703)
103. Xu H, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Inves. 2003;112(12):1821-1830. (Pubitemid 38063705)
104. Glass CK, Olefsky JM. Inflammation and lipid signaling in the etiology of insulin resistance. Cell Metab. 2012;15(5):635-645.
105. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011;11(2):98-107.
106. Pilon G, Dallaire P, Marette A. Inhibition of inducible nitric-oxide synthase by activators of AMP-activated protein kinase: a new mechanism of action of insulin-sensitizing drugs. J Biol Chem. 2004;279(20):20767-20774. (Pubitemid 38656473)
107. Sag D, Carling D, Stout RD, Suttles J. Adenosine 5′-monophosphate- activated protein kinase promotes macrophage polarization to an anti-inflammatory functional phenotype. J Immunol. 2008;181(12):8633-8641.
108. Yang Z, Kahn BB, Shi H, Xue BZ. Macrophage alpha1 AMP-activated protein kinase (alpha1AMPK) antagonizes fatty acid-induced inflammation through SIRT1. J Biol Chem. 2010;285(25):19051-19059.
109. Galic S, et al. Hematopoietic AMPK beta1 reduces mouse adipose tissue macrophage inflammation and insulin resistance in obesity. J Clin Invest. 2011;121(12):4903-4915.
110. O'Neill LA, Hardie DG. Metabolism of inflammation limited by AMPK and pseudo-starvation. Nature. 2013;493(7432):346-355.
111. Goossens GH, et al. Expression of NLRP3 inflammasome and T cell population markers in adipose tissue are associated with insulin resistance and impaired glucose metabolism in humans. Mol Immunol. 2012;50(3):142-149.
112. Maciver NJ, Michalek RD, Rathmell JC. Metabolic regulation of T lymphocytes. Annu Rev Immunol. 2013;31:259-283.
113. Choi AMK, Nakahira K. Dampening insulin signaling by an NLRP3 'meta-flammasome'. Nat Immunol. 2011;12(5):379-380.
114. Salminen A, Ojala J, Kaarniranta K, Kauppinen A. Mitochondrial dysfunction and oxidative stress activate inflammasomes: impact on the aging process and age-related diseases. Cell Mol Life Sci. 2012;69(18):2999-3013.
115. Lee HM, Kim JJ, Kim HJ, Shong M, Ku BJ, Jo EK. Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes. Diabetes. 2013;62(1):194-204.
116. Baur JA, Ungvari Z, Minor RK, Le Couteur DG, de Cabo R. Are sirtuins viable targets for improving healthspan and lifespan? Nat Rev Drug Discov. 2012;11(6):443-461.
117. Nogueiras R, et al. Sirtuin 1 and sirtuin 3: physiological modulators of metabolism. Physiol Rev. 2012;92(3):1479-1514.
118. Dolinsky VW, Chan AY, Robillard Frayne I, Light PE, Des Rosiers C, Dyck JR. Resveratrol prevents the prohypertrophic effects of oxidative stress on LKB1. Circulation. 2009;119(12):1643-1652.
119. Choudhury M, Qadri I, Rahman SM, Schroeder-Gloeckler J, Janssen RC, Friedman JE. C/EBPbeta is AMP kinase sensitive and up-regulates PEPCK in response to ER stress in hepatoma cells. Mol Cell Endocrinol. 2011;331(1):102-108.
120. da Luz G, et al. Endurance exercise training ameliorates insulin resistance and reticulum stress in adipose and hepatic tissue in obese rats. Eur J Appl Physiol. 2011;111(9):2015-2023.
121. de Lemos ET, Oliveira J, Pinheiro JP, Reis F. Regular physical exercise as a strategy to improve antioxidant and anti-inflammatory status: benefits in type 2 diabetes mellitus. Oxid Med Cell Longev. 2012;2012:741545.
122. Wu J, et al. The unfolded protein response mediates adaptation to exercise in skeletal muscle through a PGC-1alpha/ATF6alpha complex. Cell Metab. 2011;13(2):160-169.
123. El-Assaad W, et al. Saturated fatty acids synergize with elevated glucose to cause pancreatic beta-cell death. Endocrinology. 2003;144(9):4154-4163. (Pubitemid 37088771)
124. Salminen A, Kaarniranta K. AMP-activated protein kinase (AMPK) controls the aging process via an integrated signaling network. Ageing Res Rev. 2012;11(2):230-241.
125. Thaler JP, et al. Obesity is associated with hypothalamic injury in rodents and humans. J Clin Invest. 2012;122(1):153-162.
126. Christ-Crain M, et al. AMP-activated protein kinase mediates glucocorticoid-induced metabolic changes: a novel mechanism in Cushing's syndrome. FASEB J. 2008;22(6):1672-1683. (Pubitemid 351811445)
127. La Montagna G, et al. Insulin resistance is an independent risk factor for atherosclerosis in rheumatoid arthritis. Diab Vasc Dis Res. 2007;4(2):130-135. (Pubitemid 47167497)
128. Houstis N, Rosen ED, Lander ES. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature. 2006;440(7086):944-948.
129. Uzun H, Konukoglu D, Gelisgen R, Zengin K, Taskin M. Plasma protein carbonyl and thiol stress before and after laparoscopic gastric banding in morbidly obese patients. Obes Surg. 2007;17(10):1367-1373.
130. Tinahones FJ, et al. Oxidative stress in severely obese persons is greater in those with insulin resistance. Obesity (Silver Spring). 2009;17(2):240-246.
131. Barbarrosa N, et al. The obese healthy paradox: is inflammation the answer? Biochem J. 2010;430(1):141-149.
132. Hardy OT, et al. Body mass index-independent inflammation in omental adipose tissue associated with insulin resistance in morbid obesity. Surg Obes Relat Dis. 2011;7(1):60-67.
133. Klöting N, et al. Insulin-sensitive obesity. Am J Physiol Endocrinol Metab. 2010;299(3):E506-E515.
134. Qatanani M, et al. Inverse regulation of inflammation and mitochondrial function in adipose tissue defines extreme insulin sensitivity in morbidly obese patients. Diabetes. 2013;62(3):855-863.
135. Manco M. Bariatric surgery and reversal of metabolic disorders. In: Bagchi B, Preuss HG, eds. Obesity: Epidemiology, Pathophysiology, and Prevention. Boca Raton, Florida, USA: CRC Press; 2012:931-940.
136. Gealekman O, et al. Depot-specific differences and insufficient subcutaneous adipose tissue angiogenesis in human obesity. Circulation. 2011;123(2):186-194.
137. Goossens GH, et al. Increased adipose tissue oxygen tension in obese compared with lean men is accompanied by insulin resistance, impaired adipose tissue capillarization, and inflammation. Circulation. 2011;124(1):67-76.
138. Civitarese AE, et al. Calorie restriction increases muscle mitochondrial biogenesis in healthy humans. PLoS Med. 2007;4(3):e76.
139. Pasarica M, et al. Adipose tissue collagen VI in obesity. J Clin Endocrinol Metab. 2009;94(12):5155-5162.
140. Tilg H, Kaser A. Gut microbiome, obesity, and metabolic dysfunction. J Clin Invest. 2011;121(6):2126-2132.
141. Johnson AM, Olefsky JM. The origins and drivers of insulin resistance. Cell. 2013;152(4):673-684.
142. Burcelin R, Garidou L, Pomie C. Immuno-microbiota cross and talk: the new paradigm of metabolic diseases. Semin Immunol. 2012;24(1):67-74.
143. Puri V, et al. Cidea is associated with lipid droplets and insulin sensitivity in humans. Proc Natl Acad Sci U S A. 2008;105(22):7833-7838. (Pubitemid 351872724)
144. Gilliam LA, Neufer PD. Transgenic mouse models resistant to diet-induced metabolic disease: is energy balance the key? J Pharmacol Exp Ther. 2012;342(3):631-636.
145. Bäckhed F, Manchester JK, Semenkovich CF, Gordon JI. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci U S A. 2007;104:979-984.
146. Carvalho BM, et al. Modulation of gut microbiota by antibiotics improves insulin signalling in high-fat fed mice. Diabetologia. 2012;55(10):2823-2834.
147. Gregor MF, et al. Endoplasmic reticulum stress is reduced in tissues of obese subjects after weight loss. Diabetes. 2009;58(3):639-700.
148. Bandyopadhyay GK, Yu JG, Ofrecio J, Olefsky JM. Increased malonyl-CoA levels in muscle from obese and type 2 diabetic subjects lead to decreased fatty acid oxidation and increased lipogenesis; thiazolidinedione treatment reverses these defects. Diabetes. 2006;55(8):2277-2285. (Pubitemid 44743625)
149. Sriwijitkamol A, et al. Effect of acute exercise on AMPK signaling in skeletal muscle of subjects with type 2 diabetes: a time-course and dose-response study. Diabetes. 2007;56(3):836-848. (Pubitemid 46348486)
150. Hojlund K, et al. AMPK activity and isoform protein expression are similar in muscle of obese subjects with and without type 2 diabetes. Am J Physiol Endocrinol Metab. 2004;286(2):E239-E244. (Pubitemid 38140315)
151. Wallace DC, Fan W. Energetics, epigenetics, mitochondrial genetics. Mitochondrion. 2010;10(1):12-31.